Dominic Piscitelli sold $97k of ORIC
Chief Financial Officer at Oric Pharmaceuticals, Inc.. 10,720 shares at an average of $9.06, traded Dec 16, 2025, filed Dec 17, 2025.
Score components
- +22RoleCFO
- +10Trade size$97k at market
- +5Share of holdings soldSold 14% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001695028-25-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 15, 2025 | MOption exercise Common Stock | +29,333 | $0.00 | $0 | 78,868 | Dec 17, 2025 |
| Dec 16, 2025 | SOpen-market sale Common Stock | -10,720 | $9.06 | $97k | 68,148 | Dec 17, 2025 |
| Dec 15, 2025 | MOption exercise Restricted Stock Unitderivative | -8,000 | $0.00 | $0 | 0 | Dec 17, 2025 |
| Dec 15, 2025 | MOption exercise Restricted Stock Unitderivative | -10,000 | $0.00 | $0 | 10,000 | Dec 17, 2025 |
| Dec 15, 2025 | MOption exercise Restricted Stock Unitderivative | -11,333 | $0.00 | $0 | 22,667 | Dec 17, 2025 |
Related signals
Other insiders at Oric Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 2Weak | Oric Pharmaceuticals, Inc. | Richard A. Heyman director | $87k 6,700 shares | -16% | |
| 12Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $181k 13,400 shares | -16% | |
| 0Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $8,103 600 shares | -1% | |
| 9Weak | Oric Pharmaceuticals, Inc. | Richard A. Heyman director | $80k 6,700 shares | -15% | |
| 39Weak | Oric Pharmaceuticals, Inc. | Jacob Chacko PRESIDENT AND CEO | $302k 33,374 shares | -5% | |
| 30Weak | Oric Pharmaceuticals, Inc. | Pratik S Multani Chief Medical Officer | $97k 10,720 shares | -14% | |
| 30Weak | Oric Pharmaceuticals, Inc. | Jacob Chacko PRESIDENT AND CEO | $462k 37,461 shares | -7% | |
| 11Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $160k 11,000 shares | -19% | |
| 43Moderate | Oric Pharmaceuticals, Inc. | Jacob Chacko PRESIDENT AND CEO | $1.1M 87,539 shares | -13% | |
| 43Moderate | Oric Pharmaceuticals, Inc. | Jacob Chacko PRESIDENT AND CEO | $1.3M 125,000 shares | -16% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.